on Gimv (EBR:GIMB)
Spineart Secures CHF 25 Million to Boost Global Growth
Gimv and EGS Beteiligungen have announced a CHF 25 million capital injection to Spineart, a medtech firm specializing in advanced spine surgery solutions, to support its global expansion. This funding aims to foster Spineart's innovation pipeline and enhance its worldwide presence, improving outcomes for spine surgery patients.
Spineart is known for its cutting-edge technologies that make spine surgeries safer and more effective. The company is expanding across Europe and the US, with ongoing FDA submissions for its BAGUERA® C cervical disc prosthesis. With strategic investments in digital navigation and robotics, Spineart is positioned to grow further.
With 360 professionals globally and projected 2025 revenues of EUR 140 million, Spineart has been experiencing consistent growth. The new investment marks a pivotal point in its expansion strategy, aligning with its goals of delivering innovative spine solutions globally.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Gimv news